Implant-Associated Anaplastic Large Cell Lymphoma

Allergan Aesthetics has begun a new campaign to track and identify patients who have had Biocell breast implants or tissue expanders to inform them of risks associated with the product, according to a press release.

The FDA issued warning letters to two breast implant manufacturers the agency contends have failed to comply with regulatory requirements.

The FDA issued draft guidance today recommending inclusion of a boxed warning on breast implant labeling to ensure women receive and understand complete information about their benefits and potential risks.